enGene Therapeutics Stock Price, News & Analysis
Company Description
enGene Therapeutics (NASDAQ: engnw) is a publicly traded company in the Biological Products, (no Diagnostic Substances) sector.
engnw stock has gained 224.3% over the past year. Shares last traded at $2.40.
On a trailing twelve-month basis, enGene Therapeutics reported net income of -$117.3M and diluted earnings per share of $2.29.
This page provides a comprehensive overview of engnw stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
enGene Therapeutics (engnw) stock last traded at $2.40, down 16.46% from the previous close. Over the past 12 months, the stock has gained 224.3%.
engnw Rankings
Latest News
enGene Therapeutics has 2 recent news articles. Of the recent coverage, 0 articles coincided with positive price movement and 1 with negative movement. Key topics include management. View all engnw news →
SEC Filings
enGene Therapeutics has filed 10 recent SEC filings, including 6 Form 8-K, 2 Form 10-Q, 2 Form S-3. The most recent filing was submitted on April 9, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all engnw SEC filings →
Financial Highlights
operating income reached -$123.2M, and net income was -$117.3M. Diluted earnings per share stood at $2.29. The company generated -$99.2M in operating cash flow. With a current ratio of 11.75, the balance sheet reflects a strong liquidity position.
Upcoming Events
Short Interest History
Short interest in enGene Therapeutics (engnw) currently stands at 583 shares, down 84.4% from the previous reporting period, representing 0.0% of the float. Over the past 12 months, short interest has decreased by 97.8%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for enGene Therapeutics (engnw) currently stands at 1.0 days, down 20% from the previous period. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The days to cover has decreased 97.7% over the past year, suggesting improved liquidity for short covering. The ratio has shown significant volatility over the period, ranging from 1.0 to 604.3 days.
engnw Company Profile & Sector Positioning
enGene Therapeutics (engnw) operates in the Biological Products, (no Diagnostic Substances) sector and is listed on the NASDAQ.
Investors comparing engnw often look at related companies in the same sector, including Aspire Biopharma Holdings Inc (ASBPW), 180 Life Sciences Corp (ATNFW), Biocardia (BCDAW), Briacell Therapeutics Corp (BCTXW), and Briacell Therapeutics Corp (BCTXZ). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate engnw's relative position within its industry.